26.5 C
Vientiane
Thursday, August 28, 2025
spot_img
Home Blog Page 379

Vectra AI Appoints New Vice President and General Manager for Asia Pacific & Japan

SINGAPORE, July 17, 2025 /PRNewswire/ — Vectra AI, the cybersecurity AI company that protects modern networks from modern attacks, today announced the appointment of Chua Hock Leng as Vice President and General Manager for Asia Pacific & Japan (APJ). In this role, Hock Leng will spearhead Vectra AI’s growth strategy across the region, focusing on deepening customer relationships, expanding the partner ecosystem, and scaling go-to-market operations to meet rising demand for advanced threat detection in hybrid and cloud environments.

With more than two decades of leadership across enterprise security, cloud infrastructure, and digital transformation, Hock Leng brings deep regional expertise and a track record of building high-performing teams. His previous leadership roles at EMC, RSA, and Pure Storage have equipped him to navigate the complexity of APJ’s diverse markets and to deliver value in highly regulated industries.

“What drew me to Vectra AI was the opportunity to help shape the future of cybersecurity in a time when traditional approaches are no longer enough,” said Hock Leng. “As organizations across APJ embrace digital transformation, securing complex environments – especially against identity-based and lateral movement attacks – is more critical than ever. Vectra’s AI-driven platform is purpose-built for this challenge, helping security teams detect and respond to real threats faster and with greater precision.”

Hock Leng sees significant opportunity in key sectors such as financial services, healthcare, critical infrastructure, and government – industries that are navigating regulatory requirements while also facing increasing cyber threats. He will prioritize building regional partner momentum, particularly with hyperscalers and MSSPs, to ensure customers benefit from a connected ecosystem of security innovation and operational excellence.

“Hock Leng is a proven leader who understands both the strategic needs of enterprise customers and the technical dynamics of cybersecurity,” said David Kluzak, Chief Commercial Officer, Vectra AI. “His deep knowledge of the region and commitment to customer success make him the ideal leader to drive our next chapter of growth across APJ.”

Under Hock Leng’s leadership, Vectra will also showcase its latest innovation in generative AI—designed to accelerate threat detection and reduce operational noise—through customer engagements, partner enablement, and executive briefings across the region.

“As a team, we’re focused on being more than just a technology vendor,” added Hock Leng. “We aim to be a strategic ally to our customers—supporting them through complexity with clarity, speed, and trust.”

Learn more about how Vectra AI protects modern networks from modern attacks by visiting our blog and following along on LinkedIn and X.

 

Coda Accelerates Global Expansion with Acquisition of European Payments Platform Recharge

  • Singapore headquartered Coda acquires Recharge, Europe’s leading prepaid payments platform, expanding global reach and deepening direct-to-consumer capabilities.
  • Built on strong partnerships with publishers like Electronic Arts, Activision, and Riot Games, the acquisition accelerates Coda’s move into new categories and consumer segments.
  • Combined business processed over US$1.75B in 2024, reaching 200M+ users across 180+ markets.

SINGAPORE and AMSTERDAM, July 17, 2025 /PRNewswire/ — Coda, a global leader in digital content monetization headquartered in Singapore, today announced it has signed a definitive agreement to acquire Recharge, Europe’s leading prepaid payments platform, headquartered in Amsterdam. The transaction brings together two profitable regional leaders with scaled businesses, complementary strengths and a shared ambition to lead the future of global digital distribution and monetization.

The acquisition accelerates Coda’s expansion beyond gaming and strengthens its ability to serve the broader digital content economy — across categories, customers, and continents — by extending its presence in Europe and building on its direct-to-consumer capabilities. For Recharge, the deal brings B2B expertise, access to deeper partnerships with top-tier digital content publishers, and a proven playbook for growth in high-growth markets, especially across Asia. Based on 2024 figures, the combined business would have processed more than US$1.75 billion in sales, served over 200 million customers, and operated in upwards of 180 markets — marking a scaled global footprint from day one.

Coda is a trusted monetization partner to the world’s leading mobile gaming and digital content publishers, including Electronic Arts, Activision, Riot Games, HoYoverse, and Moonton. Coda distributes more than 500 titles from over 300 publisher partners and powers webstores for flagship franchises such as Call of Duty®: Mobile and EA SPORTS FC™ Mobile. With a network of over 400 local payment channels, Coda offers consumers better value and more choice. For publishers, Coda simplifies global growth —managing risk, compliance, and customer support as Merchant of Record.

Recharge — a European leader in prepaid digital storefronts like Recharge.com and Startselect.com — strengthens Coda’s B2C scale and reach across Europe. With over 16,000 products spanning gaming, mobile, gift cards, and lifestyle, Recharge combines a marketing-led, consumer-first approach with established brand equity and a user base of more than 8 million. Trusted by over 1,000 global brands — including Apple, Google, Vodafone, and PlayStation — Recharge brings retail strength, relevance, and regional depth.

“We’ve long admired what the Recharge team has built — a profitable, consumer-focused business with top global brands and real depth across Europe,” said Shane Happach, CEO of Coda.

“This transaction brings together two regional commerce leaders with distinct but highly complementary strengths. At Coda, we’ve focused on scaling our B2B capabilities alongside, working with the world’s leading digital publishers to maximize their revenue — particularly in high-growth, complex markets across Southeast Asia. Recharge adds a powerful direct-to-consumer engine, deep prepaid expertise, and strong brand equity across Europe. Most importantly, we’re bringing together two teams that share the same values: ambition, collaboration, and commercial sharpness. That gives us a strong foundation to lead the next chapter in global digital content distribution and monetization.”

“At Recharge, we’ve focused on building the technology platform that connects and scales the prepaid payments ecosystem — enabling seamless transactions between users, products, and brands through smart, data-driven infrastructure,” said Günther Vogelpoel, CEO of Recharge. “That focus, combined with a passionate team that consistently executes with precision, and pace, has allowed us to scale a profitable and trusted business across Europe and beyond.”

“Joining forces with Coda gives us the opportunity to take everything we’ve built — from our platform to our partnerships — and extend it globally to truly become the global leader we set out to be. With complementary strengths and a shared DNA, this unique combination sets us up to create even more value for the brands, publishers, and customers we serve.”

From premium content to prepaid products, this transaction brings together payments expertise, publisher and brand partnerships, and broad consumer reach — opening up real opportunities for cross-sell and deeper market access. With complementary capabilities, wider global coverage, and an expanded catalogue, Coda and Recharge are better positioned to collectively serve the full digital content economy across both B2B and B2C. Together, the combined company will deliver improved value and convenience to partners and consumers worldwide through secure, trusted, and locally relevant monetization and distribution solutions.

The transaction is backed by Apis Partners, Insight Partners, Smash Capital alongside Coda’s other investors.

Images
Available here.

Brand New TV Show “AI for Humans” Officially Premieres Exploring the Limitless Potential of Artificial Intelligence in Hong Kong


HONG KONG SAR – Media OutReach Newswire – 17 July 2025 – The brand-new TV show “AI for Humans” will premiere on 19 July (Saturday) at 8:30 PM on HOY TV Channel 78. This 17-episode series focuses on Artificial Intelligence (AI), inviting viewers to explore how AI is shaping the future and driving Hong Kong to become a global innovation and technology hub. Supported by Cyberport and hosted by Mr Nicholas Chan Hiu-Fung, BBS, MH, JP, Hong Kong Deputy to the National People’s Congress and Cyberport Board Member, the programme brings together over 70 distinguished guests. These include honorable government officials, representatives from key I&T enterprises, Cyberport unicorns, Cyberport-incubated entrepreneurs, industry leaders, academic experts, and investors, who will discuss AI’s applications and developments across various sectors.

AI for Humans

The series will showcase how Hong Kong leverages AI to advance smart city development, stimulate cross-industry synergy, and facilitate digital transformation across sectors. It offers viewers a comprehensive perspective on how AI is transforming city landscapes, driving industry upgrades, and improving citizens’ quality of life.

Over 70 Distinguished Guests include, including but are not limited to:

  • Professor Sun Dong, JP, Secretary for Innovation, Technology and Industry
  • Mr Simon Chan Sai-Ming, BBS, JP, Chairman of Hong Kong Cyberport Management Company Limited
  • Dr Rocky Cheng, JP, CEO of Cyberport
  • Ir Tony Wong Chi-kong, JP, Commissioner for Digital Policy, Digital Policy Office
  • The Hon Rosanna LAW Shuk-pui, JP, Secretary for Culture, Sports and Tourism
  • The Hon Mable CHAN, JP, Secretary for Transport and Logistics
  • Mr Joseph Chan Ho-lim, JP, Under Secretary for Financial Services and the Treasury
  • Mr Victor Tai Sheung-shing, JP, Under Secretary for Housing
  • Mr Hendrick Sin Hon-Tik, MH, JP, Chairman of the Artificial Intelligence Funding Scheme Advisory Committee
  • Mr Duncan Yau, Legislative Council Member (Technology and Innovation Constituency)
  • Mr Chris Yeung Chin-pang, Assistant Director (Property Management), Hong Kong Housing Society
  • Professor Alexander Wai Ping-Kong, JP, President and Vice-Chancellor of Hong Kong Baptist University
  • Professor Yike GUO, BSc, PhD, Provost of the Hong Kong University of Science and Technology and the Director of the Hong Kong Generative AI Research and Development Centre
  • Professor Hongxia Yang, Executive Director of PolyU Academy for Artificial Intelligence and Associate Dean (Global Engagement) of the Faculty of Computer and Mathematical Sciences, The Hong Kong Polytechnic University
  • Ir Professor Thomas Ho On-Sing, Chairman of the Construction Industry Council
  • Mr Alvin Kwock, CEO and Co-Founder of AIFT
  • Mr Guo Yong, Founder and Chairman of China Year (Beijing) Technology Co. Ltd
  • Dr Tao Xiaodong, Executive Director of iFLYTEK – Xunfei Healthcare Tech Co Ltd (2506.HK)
  • Mr Sam Kwong, Senior Director of Product Management, Klook
  • Mr Calvin Ng, CEO of ZA Bank

… And many more.

Episode 1: Star-Studded Premiere – Hong Kong’s AI Ecosystem Unveiled

“Collaboration among the Government and the industry, academia, research and investment sectors

The highly anticipated first episode will air on 19 July 2025 (Saturday) at 8:30 PM, uncovering the intricate ecosystem of AI development in Hong Kong. The episode focuses on the collaboration between five key sectors: the Government and the industry, academia, research and investment sectors, showcasing how these domains synergise to position Hong Kong as a leading smart city. Viewers will gain insights into how government policies are strengthening research capabilities, accelerating innovation commercialisation, and fostering a comprehensive innovation and technology ecosystem to give Hong Kong a competitive edge in the global tech race.

Episode 1 Highlights:
Prominent figures will share their visions, including Professor Sun Dong, JP (Secretary for Innovation, Technology and Industry), Mr Simon Chan Sai-Ming, BBS, JP (Chairman of Hong Kong Cyberport Management Company Limited), Dr Rocky Cheng, JP (CEO of Cyberport), Ir Tony Wong Chi-kong, JP (Commissioner for Digital Policy), The Hon Rosanna LAW Shuk-pui, JP (Secretary for Culture, Sports and Tourism), The Hon Mable CHAN, JP (Secretary for Transport and Logistics), Mr Joseph Chan Ho-lim, JP (Under Secretary for Financial Services and the Treasury), Ir Victor Tai Sheung-shing, JP (Under Secretary for Housing). In the second segment, industry leaders such as Mr Calvin Ng (CEO of ZA Bank), Mr Sam Kwong (Senior Director of Product Management at Klook), and Dr Tao Xiaodong (Executive Director of iFLYTEK – Xunfei Healthcare) will discuss diverse AI applications, from finance and healthcare to tourism and academia.

Sneak Peek: Upcoming Episodes

“AI for Humans” will explore AI’s impact across various sectors in the following episodes,

Episode 1 Strengthening Hong Kong’s AI Ecosystem through Collaboration:how the Government and the industry, academia, research and investment sectors work in synergy to transform Hong Kong into an AI-powered smart city.
Episode 2 AI innovation in Hong Kong and Supercomputing power.
Episode
3 & 4
AI applications in the financial sector, improving services, compliance, and efficiency.
Episode 5 AI in smart tourism, enabling personalised travel experiences.
Episode 6 AI-driven digital transformation in logistics and new opportunities in the low-altitude economy.
Episode 7 AI breakthroughs in diagnosis, treatment, and patient management in healthcare.
Episode 8 Generative AI’s role in arts and culture, preserving traditional Chinese heritage.
Episode 9 The AI+ Era: Becoming an irreplaceable talent and seizing opportunities in the AI field!
Episode 10 Data Demystified: Practical examples to help you understand the power of data-driven business!
Episodes
11-16
AI applications in education, property management, transportation, construction, manufacturing, and cybersecurity.
Episode 17 AI+ era: Future opportunities and challenges i

Broadcast Schedule
First-run: Saturdays at 8:30 PM, HOY TV Channel 78
Re-run: Sundays at 6:30 PM, HOY TV Channel 77; Tuesdays at 10:00 PM, HOY TV Channel 78
Online Viewing:
Episodes will be available on HOY TV’s official online platform: https://hoy.tv/

Hashtag: #AIforHumans #HOYTV

The issuer is solely responsible for the content of this announcement.

Nature Medicine Published Phase 1 Results of Innovent Biologics’ Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

SAN FRANCISCO and SUZHOU, China, July 17, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that Nature Medicine (IF: 58.7) has published the results of the Phase 1 clinical study of IBI343, an innovative anti-CLDN18.2 ADC, for the treatment of advanced gastric/gastroesophageal junction (G/GEJ) adenocarcinoma[Link]. Publication in this leading international academic journal indicates the strong recognition of the therapy’s clinical potential and marks another significant milestone in China’s progress in developing novel anti-tumor medications. Based on the study findings, a multi-regional Phase 3 clinical trial (G-HOPE-001, NCT06238843) was launched in 2024 to further evaluate IBI343 as a safe and effective treatment option for patients with advanced G/GEJ AC.

Gastric cancer remains one of the most common malignant tumors in the world. According to the GLOBOCAN 2022 statistics, it ranks as the fifth most common malignant tumor and the fifth leading cause of cancer-related death globally, with an estimated 970,000 new cases and 660,000 deaths annually. Each year, China reports 359,000 new cases and 260,000 deaths from gastric cancer, representing 37.0% and 39.4% of global totals, respectively, highlighting a significant unmet medical need.

CLDN 18.2 is a tight junction protein expressed in differentiated epithelial cells on the gastric mucosa under normal physiological conditions. Previous studies have revealed that Claudin18.2 is highly expressed in multiple types of cancer, including gastric cancer (60-80%), pancreatic cancer (50%), esophageal carcinoma (30-50%), and lung cancer (40-60%). Targeting CLDN18.2 with monoclonal antibodies (mAbs) and ADCs represents a promising new approach for treating gastric cancer.

This published study is a global, multicenter Phase 1 clinical trial (ClinicalTrial.gov identifier: NCT05458219) designed to evaluate the safety, tolerability and preliminary efficacy of IBI343 in patients with advanced solid tumors. Between October 26, 2022, and June 30, 2024, a total of 116 subjects with advanced G/GEJ adenocarcinoma were enrolled to receive IBI343 monotherapy (8 in escalation and 108 in expansion).

IBI343 has demonstrated encouraging tumor response and survival benefit

The study analyzed the efficacy data of evaluable subjects with high expression of CLDN18.2 (≥75% tumor cells with membranous staining intensity ≥2+ by IHC), in the two dose groups of 6 mg/kg and 8 mg/kg.

  • At 6 mg/kg (N=31), 15 patients had partial responses (PR) including 9 patients with confirmed PRs and 1 patient awaiting confirmation. The confirmed ORR was 29.0% (95% CI: 14.2-48.0) and the disease control rate (DCR) was 90.3% (95% CI: 74.2-98.0). In 9 patients with confirmed response, the median duration of response (DoR) was 5.6 months (95% CI: 2.8-7.0). The median follow-up was 10.6 months (95% CI: 9.7-11.5) for PFS and OS. The median PFS was 5.5 months (95% CI: 4.1-7.0). OS data was not mature with the current median OS of 10.8 months (95% CI: 6.8-NC). After data cutoff, response of the remaining 1 patient was confirmed on July 26, 2024 and the confirmed ORR was updated to 32.3% (95% CI: 16.7-51.4).
  • At 8 mg/kg (N=17), 17 patients with high expression of CLDN 18.2 were evaluable. Among them, 9 patients had PRs including 8 patients had confirmed PR. The confirmed ORR 47.1% (95% CI: 23.0-72.2), and the DCR was 88.2% (95% CI: 63.6-98.5). In eight patients with confirmed response, the median DoR was 5.7 months (95% CI: 2.7-NC). Of all G/GEJ adenocarcinoma patients with high CLDN18.2 expression treated at 8 mg/kg (N=19, including 1 patient from dose escalation and 18 patients from dose expansion), the median follow-up was 8.1 months (95% CI: 7.6-8.5) for PFS and OS. The median PFS was 6.8 months (95% CI: 2.8-7.5), and the median OS was not reached with events occurred in 36.8% patients.

IBI343 also demonstrated superior safety

  • Among all patients with G/GEJ adenocarcinoma (n=116, including 8 patients with gastric cancer from the dose escalation phase), 66.4% patients (77/116) had ≥3 grade TEAEs. The most common ≥3 grade TEAEs (≥35%) were neutrophil count decreased (28.4%), white blood cell count decreased (25.9%), and anemia (16.4%). There were very few grade 3 gastrointestinal adverse events, including only 1.7% of grade 3 nausea. No interstitial lung disease of any grade was reported. Treatment-related toxicity was alleviated with adequate supportive treatment, and the overall safety was tolerable.

Integrated pharmacokinetics (PK), exposure-response, safety, and efficacy data supported 6 mg/kg Q3W as the recommended Phase 2 dose (RP2D) of IBI343. This provides support for the conduct of subsequent Phase 3 trial, suggesting that IBI343 may become a new treatment option for patients with gastric cancer in the future.

Professor Lin Shen, Corresponding Author, Leading Principal Investigator, from Beijing Cancer Hospital, said, “Following the eras of chemotherapy, targeted therapy and immunotherapy, ADCs have opened a new frontier in the treatment of gastrointestinal tumors. IBI343 is a new generation of Fc-silent anti-CLDN18.2 ADC that has shown encouraging clinical benefits and low gastrointestinal toxicity in Phase 1 studies. We look forward to the results of the Phase 3 study comparing IBI343 with standard treatment, aiming to ultimately reshape clinical practice, transform treatment paradigms, and usher in a new chapter in precision medicine.”

Dr. Hui Zhou, Chief R&D Officer for Oncology Pipeline at Innovent Biologics, said, “There is a huge unmet clinical need for the treatment of advanced gastric cancer. The Phase 1 study results of IBI343 in advanced gastric and gastroesophageal junction adenocarcinoma, now published in the top international journal, Nature Medicine, further verify the clinical value of IBI343 in this population. We will work with researchers worldwide to advance the multi-regional Phase 3 clinical trial (G-HOPE-001), with the goal of establishing a new paradigm in clinical diagnosis and treatment and ultimately benefiting gastric cancer patients around the world. We are also exploring the therapeutic potential of IBI343 in pancreatic cancer and other indications.”

About Gastric/ Gastroesophageal Junction Adenocarcinoma

Gastric cancer is one of the most prevalent malignant tumors worldwide and a leading cause of cancer-related deaths globally. The 5-year survival rate of patients with metastatic gastric cancer is less than 5%[i]. China and Japan have the highest incidence rates of gastric cancer[ii]. Currently, the standard-of-care treatments for patients with advanced metastatic gastric cancer include a chemotherapy combination of fluoropyrimidine and platinum, as well as immune checkpoint inhibitor therapy. However, systemic therapy has limited efficacy in advanced gastric cancer. In particular, the prognosis for patients with third-line or higher gastric cancer is usually poor, with fewer treatment options and shorter survival expectations. The median survival time for these patients is only about 0.5 year[iii].

Claudin, a member of the tight junction molecule family, is a key structural and functional component of epithelial tight junctions. Among them, CLDN18.2 is normally buried in gastric mucosa, but the development of malignancy leads to disruption of tight junctions and exposure of CLDN18.2 epitopes on the membrane of tumor cells[iv]. CLDN18.2 is expressed in up to 80% of patients with gastric cancer.

About IBI343Anti CLDN18.2 ADC

IBI343 is a recombinant human anti-CLDN18.2 monoclonal antibody-drug conjugate (ADC) developed by Innovent Biologics. It specifically binds to the tumor cells expressing CLDN18.2, triggering CLDN18.2-dependent internalization of the ADC. Once inside the cell, the cytotoxic payload is released, resulting in DNA damage and ultimately apoptosis of the tumor cells. The released drug can also diffuse across the plasma membrane to reach and kill neighboring cells, resulting in a “bystander killing effect”.

As an innovative TOPO1i ADC, IBI343 has demonstrated tolerable safety and encouraging efficacy signals in this Phase 1 clinical studies. The therapeutic potential of IBI343 is currently being explored in tumor types such as gastric cancer and pancreatic cancer.

The multi-regional Phase 3 clinical trial of IBI343 for advanced gastric / gastroesophageal junction adenocarcinoma is now recruiting patients (G-HOPE-001, NCT06238843). The relevant indication has been granted Breakthrough Therapy Designation (BTD) by China’s NMPA .

The multi-regional Phase 1 clinical trial of IBI343 for advanced pancreatic ductal adenocarcinoma is also enrolling patients (NCT05458219). This indication has received Fast Track Designation (FTD) from the U.S. FDA and been granted BTD by China’s NMPA.

About Innovent Biologics

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement:

1.Innovent Biologics does not recommend the use of unapproved drugs/indications.

2.Ramucirumab injection (Cyramza®), selpercatinib capsules (Retsevmo®) and pirtobrutinib tablets (Jayprica®) were developed by Eli Lilly and Company

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent Biologics, Inc. (“Innovent” or “Company”), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company’s competitive environment and political, economic, legal and social conditions.

The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect.

References

[i] Lasithiotakis K, Antoniou SA, Antoniou GA, Kaklamanos I, Zoras O. Gastrectomy for stage IV gastric cancer. a systematic review and meta-analysis. Anticancer Res. May 2014;34(5):2079-85

[ii] Xu B, Wang JM. Epidemiological study of gastric cancer[J]. Chin J Cancer Prev Treat, 2006,13(1): 81-87.

[iii] Chan WL, Lam KO, So TH, et al. Third-line systemic treatment in advanced/metastatic gastric cancer: a comprehensive review. Ther Adv Med Oncol. 2019;11:1758835919859990.

[iv] Sahin U, Koslowski M, Dhaene K, et al. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. Clin Cancer Res. 2008;14(23):7624-7634.

 

BEYOND Expo 2026 Returns to Macao on May 27-30, Unveiling Its Most Ambitious and Globally Connected Edition Yet

Larger in scale, deeper in content, and broader in reach — BEYOND Expo strengthens its position as Asia’s largest tech ecosystem event.

MACAO, July 17, 2025 /PRNewswire/ — BEYOND Expo, Asia’s most influential and largest ecosystem platform for innovation, technology, and cross-border collaboration, will return for its 2026 edition from May 27–30, 2026, at the Venetian Cotai Expo in Macao, China.

Image: BEYOND Expo returns to Macao on May 27-30, 2026, under the theme “Empowering Asia, Bridging the World”.
Image: BEYOND Expo returns to Macao on May 27-30, 2026, under the theme “Empowering Asia, Bridging the World”.

Following the record-setting success of BEYOND Expo 2025 — attended by over 25,000 professionals, 800+ global exhibitors, and 800+ investors — this next edition will expand significantly in depth, scope, and global reach under the theme: “Empower Asia, Bridging the World.”

BEYOND Expo 2026 will reinforce its role as the central platform where entrepreneurship, capital, and policy intersect — driving breakthrough innovation, global partnerships, and business transformation across sectors.

“Asia is no longer just a market, it’s a powerhouse for global innovation,” said Jason Ho, Co-Founder of BEYOND Expo. “In 2026, BEYOND Expo will deepen its mandate as a cross-border catalyst, empowering collaboration between innovators, investors, corporates, and policymakers. Our upcoming edition will be more ambitious in every dimension: broader in regional representation, deeper in content, and more immersive across experiences.”

Highlights of BEYOND Expo 2026

In 2026, BEYOND Expo will present a larger-scale exhibition with 1,200+ expected exhibitors, spotlighting cutting-edge innovation from across Asia and beyond. Visitors will get direct exposure to Asia’s most dynamic startups, advanced hardware, robotics, and next-gen AI solutions — showcasing the region’s rising strength in deep tech and industrial innovation. BEYOND Expo promises to offer a distinct look at Asia’s innovation edge, a draw for tech buyers seeking real solutions and future-ready products.

BEYOND Expo 2026 will also offer immersive summits, curated investor programs, and region-focused platforms, all designed to attract global participation and drive real business outcomes.

Fund at First Pitch (FAFP): Where Ideas Meet Capital

Returning in 2026, Fund at First Pitch (FAFP) will spotlight Asia’s most promising early-stage startups, connecting them directly with over 200 global investors — including institutional investors, VCs, and family offices. As one of BEYOND Expo’s flagship initiatives, FAFP unites high-potential founders with global capital under one roof, accelerating cross-border deal flow and regional expansion. Since 2024, more than 300 startups have taken the BEYOND stage, reinforcing its position as a powerful gateway for investment, visibility, and growth.

BEYOND Media Day: Shaping Global Narratives

Building on the momentum of 2025 — where over 100 global media outlets gathered for an exclusive preview — BEYOND Media Day returns in 2026 with expanded reach, deeper content, and elevated visibility for exhibitors and sponsors.

This media-only experience offers early access to breakthrough innovations across AI, robotics, consumer technology, and sustainability. In 2025, attendees included top-tier journalists and digital influencers from platforms such as Bloomberg TV, CNN, FOX News Channel, Capital Magazine, Caixin Global, and Phoenix TV. Designed to maximize global exposure, BEYOND Media Day delivers unmatched storytelling opportunities, drawing the attention of influential voices covering the technologies and companies shaping the future.

BEYOND Innovation Awards: Expanding Recognition Across Asia

The BEYOND Awards 2026 will feature new categories and a stronger focus on emerging Asian innovators. In addition to its current verticals in AI, climate tech, healthcare, and consumer innovation, next year’s Awards will include industrial design and other frontier sectors, recognizing companies that are creating real-world impact through product excellence and transformative thinking.

Cross-Regional Forums: Bridging Borders and Ideas

BEYOND Expo 2026 will feature an expanded portfolio of cross-regional summits, reinforcing its role as a hub for global innovation diplomacy. Confirmed forums include the Asia–Europe Tech Forum, Japan Tech Forum, Middle East Tech Forum, Southeast Asia’s ORIGIN Conference, and the Asia–Latam Tech Forum. These curated platforms foster collaboration among governments, corporates, and innovators, while highlighting emerging trends from key ecosystems.

In line with BEYOND’s mission to empower Asia and promote cross-border collaboration, the landmark BGlobal Summit and Global Investment Summit will return at an even larger scale. These high-level forums connect international investors and multinational corporates with Asia’s most promising startups, driving dialogue, investment, and regional expansion — and strengthening BEYOND’s commitment to helping founders and funds go global.

SheTech Summit: Driving Inclusive Innovation

Women remain underrepresented in tech globally. SheTech Summit is a dedicated platform to highlight and support female founders, executives, and investors across Asia. This year, BEYOND Expo will partner with leading international communities to position SheTech as Asia’s premier gathering for women in tech and innovation — providing mentorship, visibility, and meaningful connections for rising female leaders.

Founder Talk & BEYOND Founders Club: Scaling Impactful Conversations

Founder Talk invites Asia’s unicorn founders, serial entrepreneurs, and disruptors to share unfiltered insights on scaling, failure, and leadership in tech. As BEYOND Expo evolves into the anchor event for Asia’s startup community, this series highlights why every ambitious founder in Asia should be at BEYOND Expo. Meanwhile, the BEYOND Founders Club, officially announced in 2025, is a purpose-driven network that unites visionary entrepreneurs, pioneering innovators, and tech influencers committed to shaping the future of global innovation.

Exclusive Wealth Programs

BEYOND Wealth Summit will once again host LPs, family offices, and private capital leaders in a closed-door, invitation-only setting, offering unique networking and relationship-building opportunities. For GPs and fund managers seeking meaningful exposure to Asia’s capital ecosystem, BEYOND Expo continues to be a strategic annual destination.

The Fun Continues: Where Culture Meets Capital

BEYOND Expo continues to redefine how business and entertainment converge. In 2026, the program will expand to include elevated networking experiences, from gala dinners and curated poolside gatherings to immersive parties, all set against the vibrant backdrop of Macao. Attendees can expect unforgettable moments featuring some of the city’s most iconic stages, creating a dynamic atmosphere where meaningful connections happen beyond the boardroom.

“BEYOND Expo is not just an event—it’s a living platform of ideas, capital, and influence,” said Dr. Lu Gang, Co-founder of BEYOND Expo. “Our mission is to position Asia as the epicenter of global tech transformation. In 2026, we’ll double down on that vision with more strategic forums, immersive content, and global partnerships that move the world forward.”

Join the Asia Tech Ecosystem at BEYOND Expo 2026

Whether you’re a startup seeking capital, a corporate exploring frontier technology, or a policymaker focused on building the future — BEYOND Expo 2026 is where global opportunity meets innovation. Visit www.beyondexpo.com to explore tickets or inquire directly about exhibiting, speaking, or media partnerships. Official ticket sales will launch soon — pre-register now to stay updated and be among the first to access tickets.

About BEYOND Expo

The BEYOND International Technology Innovation Expo (BEYOND Expo) is Asia’s leading annual technology event. Serving as a dynamic platform since 2021, BEYOND Expo not only showcases global technological innovations but also provides a unique opportunity to foster innovation upgrades across diverse industries and regions.

BEYOND Expo has attracted participation from Asia’s Fortune 500 companies, multinational corporations, unicorn companies, and emerging startups. Through a multifaceted approach involving expos, summits, and various activities, BEYOND Expo has successfully cultivated an innovative ecosystem, propelling collective development in the Asia-Pacific region and the global technology innovation industry. www.beyondexpo.com

SUNRATE Awarded In CNBC’s World’s Top Fintech Companies 2025 List


SINGAPORE – Media OutReach Newswire – 17 July 2025 – SUNRATE, the global payment and treasury management platform, announced today that it has been included in the prestigious CNBC’s list of the World’s Top Fintech Companies 2025.

CNBC, a world leader in business news partnered with Statista, a global data and business intelligence platform, to identify the top fintech companies from around the world. The World’s Top FinTech Companies 2025 list is based on the analysis and weighting of overarching KPIs like Payments, Alternate Finance, Financial Planning, Digital Assets, Neobanking, Wealth Technology, Business Process Solutions, and Banking Solutions. These segment-specific KPIs were derived from the following research methods:

  • Publicly Available Data Points: In-depth research into relevant KPIs for more than 2,000 eligible companies was conducted using publicly available sources such as annual reports, company websites, and media monitoring.
  • Open Online Application: More than 100 companies had the opportunity to be considered for the top list by submitting relevant KPIs.

“It’s a proud moment for SUNRATE to be recognised on CNBC’s list of the World’s Top Fintech Companies,” said Paul Meng, Co-founder of SUNRATE. “Since day one, our strategic vision has been to revolutionise global B2B payments by building a global clearing network and harnessing blockchain technology to deliver secure, efficient, compliant, and transparent cross-border payment solutions. This milestone reflects the trust our global clients place in us.”

Meng added, “As we scale further, we remain focused on expanding our capabilities and global reach to support the full spectrum of businesses—from small and medium-sized enterprises (SMEs) to large corporates—empowering them to thrive in today’s fast-evolving global commerce landscape.”

Hashtag: #SUNRATE

The issuer is solely responsible for the content of this announcement.

About SUNRATE

SUNRATE is a global payment and treasury management platform for businesses worldwide. Since its inception in 2016, SUNRATE has been recognised as a leading solution provider and has enabled companies to operate and scale both locally and globally in 190+ countries and regions with its cutting-edge proprietary platform, extensive global network, and robust APIs.

With its global business headquarters in Singapore and offices in Hong Kong, Jakarta, London, and Shanghai, SUNRATE partners with the top global financial institutions, such as Citibank, Standard Chartered, Barclays, J.P. Morgan and is the principal member of both Mastercard and Visa. To learn more about SUNRATE, visit

Kavalan, Golden Blue Launch ‘Team Kavalan 2.0’ – A Toast to South Korea’s Finest Bars

Back by Popular Demand After a Stellar First Season

TAIPEI, July 17, 2025 /PRNewswire/ — After the overwhelming success of its inaugural campaign, Kavalan, Taiwan’s award-winning single malt whisky, is teaming up once again with long-time exclusive South Korean partner Golden Blue to launch the second edition of ‘Team Kavalan’—a nationwide celebration of creativity, craftsmanship, and world-class whisky.

Team Kavalan returns in 2025 with top Korean bartenders reimagining Kavalan through dual-bar cocktail collaborations across South Korea.
Team Kavalan returns in 2025 with top Korean bartenders reimagining Kavalan through dual-bar cocktail collaborations across South Korea.

“One Whisky, Two Perspectives” will feature eight world-class Korean bartenders across 12 months, pairing up to collaborate in crafting two distinct signature cocktails that offer contrasting interpretations of Kavalan. Each pair of cocktails will be promoted simultaneously for three months at two different bars, creating a dynamic, dual-location experience.

The campaign will unfold in waves throughout 2025, with the first collaboration already confirmed:

  • May 2025: Best & Best – Distillery Select No.1
    Bar Cham vs Bar Sookhee

This opening match features two of Korea’s most iconic bartenders. Bar Cham and Bar Sookhee are widely recognized across the industry, with their influence deep and far reaching. As top talents in the Korean cocktail scene, their participation sets the tone for what’s to come.

Additional pairings and themes will be revealed progressively as part of the campaign rollout.

Alongside these signature serves, guests can savor a curated flight of Kavalan single malts, enjoyed neat to fully appreciate the whisky’s depth, elegance, and complexity.

“We’re thrilled to bring ‘Team Kavalan’ back for a second year,” said Golden Blue CEO Ms. Park Soyoung. “Last year’s campaign brought to life the vibrant versatility of Kavalan in stunning cocktails featuring expressions like Distillery Select No.1, Triple Sherry Cask, and Kavalan Classic. This year, we are excited to collaborate with even more bars in Korea to enhance Kavalan’s brand value and deliver diverse experiences.”

As Kavalan continues its impressive growth in South Korea, one of its fastest growing and most strategic global markets, this collaboration underscores the strength of its partnership with Golden Blue.

“Golden Blue has been instrumental in driving Kavalan’s success here,” said Mr. Y.T. Lee, Chairman of King Car Group. “South Korea saw triple-digit sales growth in 2023, and Golden Blue has continued that growth trajectory strongly into 2024 with further double-digit increases.”

Kavalan will also attend this year’s high-end trend-leading Seoul Int’l Bar & Spirits Show from July 25 to 27, Asia’s leading bar and spirits exhibition.

South Korean whisky fans can enjoy 7 Kavalan expressions in the domestic market, including:

Distillery Select No.1, Classic, Triple Sherry Cask, Oloroso Sherry Oak, Solist Oloroso Sherry Cask, Vinho Barrique, and Port Cask. In the duty-free sector, additional favorites such as Concertmaster Port Cask Finish, Solist ex-Bourbon, Solist Fino Sherry, Solist PX Sherry, Master’s Select Series, Grand Reserve Series, and Distiller’s Reserve Series are also available.

About Golden Blue 

Founded in 2003 and headquartered in both Busan and Seoul, Golden Blue is one of Korea’s leading spirits companies. Golden Blue is active in whisky, herbal liquor, and global spirits distribution. The name “Gold” symbolizes tradition and authority, while “Blue” represents innovation and new value. This reflects the company’s mission to open new horizons in the Korean liquor market by presenting fresh value while honoring heritage.

Golden Blue was recognized in Forbes Asia’s 200 Best Under A Billion list in 2019.

Since 2017, Golden Blue has been the exclusive importer and distributor of Kavalan in South Korea. Kavalan is Taiwan’s pioneering single malt whisky brand, internationally awarded and exported to over 50 countries.

About Kavalan Whisky

Kavalan Distillery in Yilan County has been pioneering the art of single malt whisky in Taiwan since 2005. Our whisky, aged in intense humidity and heat, sources the crystal meltwaters of Snow Mountain and is enhanced by sea and mountain breezes. These conditions combine to create Kavalan’s signature creaminess. Taking Yilan County’s old name, our distillery is backed by more than 45 years of beverage-making under parent company, King Car Group. We have collected 900 gold awards or higher from the industry’s most competitive contests.

Media Contact information

Kaitlyn Tsai
kaitlyn@kingcar.com.tw 

Britney Chen
britneychen@kingcar.com.tw

LIVE FEED: DISNEY CEO BOB IGER TO RING NYSE OPENING BELL FROM DISNEYLAND RESORT

NEW YORK, July 17, 2025 /PRNewswire/ — On Thursday morning, the New York Stock Exchange will provide a live broadcast of Disney CEO Bob Iger ringing the NYSE Opening Bell from Disneyland Resort in Anaheim, California, in celebration of Disneyland’s 70th anniversary. NYSE President Lynn Martin will join Mr. Iger to commemorate the occasion.

When:
Thursday, July 17, 2025
9:28 a.m. ET     Live feed opens
9:30 a.m. ET     Opening Bell rings
9:31 a.m. ET     Live feed closes

Live Feed:
The live feed will be available via Encompass 4090 and The Switch. Additional requests should be made through the NYSE Broadcast Center at NYSETV@NYSE.com or 212.656.5483.

Live Stream:
The live feed also will be streamed on the NYSE’s channels on X, LinkedIn and YouTube.